Importantly, Ruxo has been utilized preclinically to treat solid tumors, with promising effects reported in ovarian cancer by suppressing stemness45, in aggressive carcinoma by antagonizing TGF-β-induced production of leukemia inhibitory factor46, and in KRAS-driven lung adenocarcinoma by decreasing tumor-promoting chemokines, cytokines, as well as immunosuppressive myeloid-derived suppressor cells71. The gene discussed is KRAS; the disease is ovarian carcinoma.